Saturday 17 October 2026
Export OGN’s income statement to Excel — free account
Organon & Co.
OGN Healthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.76
0.00
0.00%
Follow OGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| 24.04% | 34.05% | 30.56% | 71.62% | ||
| 1.57% | 1.88% | 1.44% | 3.81% | ||
ROIC |
6.11% | 6.18% | 5.84% | 8.30% | |
Return on Tangible Assets |
5.53% | 6.63% | 5.73% | 15.13% | |
Average Days of Receivables |
88.88 | 81.97 | 78.16 | 85.96 | |
Free Cash Flow per Share |
1.77 | 2.63 | 1.60 | 2.40 | |
Free Cash Flow |
464.00 | 684.00 | 415.00 | 624.00 | |
Capital Expenditures |
(273.00) | (166.00) | (285.00) | (325.00) | |
| Other line items | |||||
Cash ROIC |
4.34% | 6.46% | 4.16% | 6.00% | |
Accounts Receivable Turnover |
4.12 | 4.34 | 4.62 | 3.98 | |
Accounts Payable Turnover |
2.74 | 2.92 | 2.76 | 2.62 | |
Inventory Turnover |
2.07 | 2.13 | 2.13 | 1.97 | |
Average Days of Payables |
132.33 | 123.38 | 119.70 | 138.37 | |
Days of Inventory on Hand |
170.10 | 172.33 | 176.78 | 191.71 | |
Tax Rate |
(0.57) | (0.54) | (0.56) | (0.29) | |
Research and Development Expense of Revenue |
5.84% | 5.89% | 5.89% | 6.43% | |
Selling, General and Administrative Expense of Revenue |
27.84% | 27.99% | 27.69% | 27.90% | |
Share Based Compensation of Revenue |
1.22% | 1.17% | 1.24% | 1.52% | |
Interest Coverage |
1.76 | 1.68 | 1.63 | 2.34 | |
Operating CF/Net income |
3.53 | 3.46 | 3.74 | 1.89 | |
Depreciation/Fixed assets |
0.46 | 0.47 | 0.47 | 0.27 | |
Capex/Depreciation |
(0.47) | (0.28) | (0.47) | (0.94) | |
Revenue per Share |
23.33 | 23.67 | 23.95 | 24.24 | |
Operating CF per Share |
2.81 | 3.26 | 2.70 | 3.65 | |
Capex per Share |
(1.04) | (0.64) | (1.10) | (1.25) | |
Capex to Sales |
0.04 | 0.03 | 0.05 | 0.05 |
Columns are period end dates